Skip to main content

Table 1 Patient characteristics at time of diagnosis

From: The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer

 

Number (%)

miRNA-126 expression level

(μm2)

 

(n = 89)

Median (95% CI)

p - value

Sex

   

   Male

45 (51)

2533 (1690-3285)

0.84

   Female

44 (49)

2354 (1650-3163)

 

Age (years)

   

   Mean (SD)

63.2 (8.2)

  

   Range

24 - 80

  

   > mean

49 (55)

2088 (1556-3223)

0.56

   < mean

40 (45)

2531 (1896-3355)

 

ECOG Performance status

   

   0

37 (42)

2041 (1551-3163)

0.40

   1-2

52 (58)

2535 (1708-3489)

 

Localization

   

   Rectum

18 (20)

3038 (1690-4030)

0.37

   Colon

71 (80)

2141 (1650-2638)

 

   Left colon

47 (66)

2141 (1589-2818)

0.99

   Right colon

24 (34)

2232 (1452-3355)

 

MSI status*

   

   MSI

8 (11)

2193 (1374-5421)

0.61

   MSS

62 (89)

2355 (1705-2818)

 

Metastatic sites*

   

   1

27 (31)

3575 (3163-4521)

< 0.0001

≥ 2

59 (69)

1857 (151-2376)

 
  1. CI confidence interval, SD standard deviation, ECOG Eastern Cooperative Oncology Group, MSI microsatellite instability, MSS , microsatellite stable
  2. *MSI status was not assessed in all patients
  3. **A reliable estimate of the number of metastatic sites was not possible in 3 patients
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us